policy paper

PhRMA Special 301 Submission 2020

The Pharmaceutical Research and Manufacturers of America (PhRMA) today called on the Office of the United States Trade Representative (USTR) to defend American biopharmaceutical innovators and jobs by ending market access and intellectual property barriers in 24 leading economies around the world. In its submission for USTR’s 2020 Special 301 Report, PhRMA called on the Trump administration to address discriminatory market access practices abroad that free ride on American innovation and put U.S. jobs and exports at risk.